Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Share:
Related LGND
18 Biggest Mid-Day Gainers For Wednesday
Retrophin Up 40% On Kidney Disease Drug Trial, Shkreli Still Wants His $25+ Million 'Hogan Reward'
Best Near-Term Price Gains Ahead For: Biotech Stocks (Seeking Alpha)
Related GSK
HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target
The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A
Janssen submits marketing application in U.S. for sirukumab for rheumatoid arthritis (Seeking Alpha)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA

 

Related Articles (LGND + GSK)

View Comments and Join the Discussion!